Schedule 13G ownership disclosure

Vera Therapeutics Inc

COMMON STOCK · CUSIP: 92337R101

Event date: 2025-09-30

Filing-level shares
3,666,598
Percent of class
5.7%
  • T. Rowe Price Associates, Inc.

    Shares: 3,666,598 · Class: 5.7%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000080255-25-000840
Form type
SCHEDULE 13G/A
Filer
PRICE T ROWE ASSOCIATES INC /MD/
CIK
CIK 80255
Filed
Nov 14, 2025
Reporting period
Sep 30, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub